The DCRU’s Robert Noveck discusses a new anticoagulant reversal agent

March 13, 2014 – If approved, Perosphere’s PER977 would be the first drug of its kind to work with new oral anticoagulants.

The DCRU’s Robert Noveck, MD, PhD, discusses the unit’s trial of PER977 with Perosphere’s James Costin, MD.